Navigation Links
Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
Date:9/24/2010

TAMPA, Fla. Moffitt Cancer Center and GLG Pharma, LLC announced today that they have entered into a licensing agreement under which GLG Pharma, LLC has acquired the exclusive worldwide rights to a technology platform that includes a series of STAT3 inhibitors. Researchers at Moffitt discovered several classes of STAT3 inhibitors and evaluated their potential pre-clinically as novel anti-cancer drugs.

"Persistently activated STAT3 is a major contributor to human cancer; validating its usefulness as a cancer therapeutic target in collaboration with GLG will be a major milestone," said Said Sebti, Ph.D., chair of the Drug Discovery Department at Moffitt.

"One of several recent startup companies to be based on Moffitt technologies, GLG brings a highly experienced management team to the mix," said Ray Carpenter, senior licensing manager of The Office of Technology Management and Commercialization at Moffitt. "Their combined experience in taking technologies through clinical trials instills confidence that these technologies surrounding an important target, like the STAT3 pathway, is being placed in capable hands. Our office is delighted that GLG Pharma will move this technology from the laboratory to the clinic to improve patient care."

Under the license agreement, GLG Pharma has agreed to pay Moffitt when various commercialization milestones are reached, as well as make royalty payments on the sales of testing services and licensed products.

"This license agreement is the first key milestone established for the company in 2010," said Hector J. Gomez, M.D., Ph.D., CEO of GLG Pharma. "We believe that STAT3 inhibitors are the next generation of targeted therapies. They are anticipated to be very specific, have a broad spectrum of activity and are expected to be well tolerated and more efficacious compounds than current therapies."


'/>"/>

Contact: Michelle Foley
MFoley@Moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
2. Cancer-associated long noncoding RNA regulates pre-mRNA splicing
3. Declining breast cancer incidence in Canada with declining HRT usage
4. Sexual Problems May Arise After Breast Cancer
5. UCLA cancer researchers discover new signaling pathway that controls cell development and cancer
6. Patients with cancer who stop hospice care boost health-care costs
7. Mammograms Cut Breast Cancer Death Rates, But Only Modestly: Study
8. David Cheresh receives top award for cancer metastasis research
9. 70 percent of women likely to experience sexual problems after breast cancer
10. Physical limitations of breast cancer survivors
11. Synthetic lethality strategy improves molecularly targeted cancer therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: